DE69534676D1 - Orale Verabreichung von chemisch modifizierten Proteinen - Google Patents

Orale Verabreichung von chemisch modifizierten Proteinen

Info

Publication number
DE69534676D1
DE69534676D1 DE69534676T DE69534676T DE69534676D1 DE 69534676 D1 DE69534676 D1 DE 69534676D1 DE 69534676 T DE69534676 T DE 69534676T DE 69534676 T DE69534676 T DE 69534676T DE 69534676 D1 DE69534676 D1 DE 69534676D1
Authority
DE
Germany
Prior art keywords
chemically modified
oral administration
modified proteins
csf
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534676T
Other languages
English (en)
Other versions
DE69534676T2 (de
Inventor
Alan D Habberfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE69534676D1 publication Critical patent/DE69534676D1/de
Publication of DE69534676T2 publication Critical patent/DE69534676T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69534676T 1994-02-08 1995-02-08 Orale Verabreichung von chemisch modifizierten Proteinen Expired - Lifetime DE69534676T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US194187 1994-02-08
US37912195A 1995-02-01 1995-02-01
US379121 1995-02-01

Publications (2)

Publication Number Publication Date
DE69534676D1 true DE69534676D1 (de) 2006-01-12
DE69534676T2 DE69534676T2 (de) 2006-08-17

Family

ID=26889779

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69534676T Expired - Lifetime DE69534676T2 (de) 1994-02-08 1995-02-08 Orale Verabreichung von chemisch modifizierten Proteinen
DE69521880T Expired - Lifetime DE69521880T2 (de) 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69521880T Expired - Lifetime DE69521880T2 (de) 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Country Status (12)

Country Link
US (2) US20020099001A1 (de)
EP (2) EP1090645B1 (de)
AT (2) ATE311908T1 (de)
AU (1) AU1916295A (de)
DE (2) DE69534676T2 (de)
DK (2) DK1090645T3 (de)
ES (2) ES2159630T3 (de)
GR (1) GR3036625T3 (de)
HK (1) HK1036214A1 (de)
IL (1) IL112583A0 (de)
PT (1) PT726778E (de)
WO (1) WO1995021629A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
ATE327254T1 (de) 1998-10-16 2006-06-15 Biogen Idec Inc Interferon-beta fusionsproteine und deren verwendungen
IL142282A0 (en) 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
BRPI0409424B8 (pt) * 2003-04-15 2021-05-25 Cantab Biopharmaceuticals Patents Ltd composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
CN101193658B (zh) 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP5570988B2 (ja) 2007-08-27 2014-08-13 ラティオファーム ゲーエムベーハー Ｇ−ｃｓｆ結合体の液体調製物
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
EP3534974B1 (de) * 2016-11-02 2024-08-21 Board of Regents, The University of Texas System Auflösbare filme und verfahren zu deren verwendung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
EP0452179B1 (de) * 1990-03-28 1996-06-12 Nippon Oil And Fats Company, Limited Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
DE69521880D1 (de) 2001-08-30
DE69521880T2 (de) 2002-01-03
WO1995021629A1 (en) 1995-08-17
DE69534676T2 (de) 2006-08-17
ATE311908T1 (de) 2005-12-15
AU1916295A (en) 1995-08-29
DK1090645T3 (da) 2006-03-27
ES2159630T3 (es) 2001-10-16
US20020099001A1 (en) 2002-07-25
EP1090645A2 (de) 2001-04-11
ES2251924T3 (es) 2006-05-16
ATE203415T1 (de) 2001-08-15
US20030185795A1 (en) 2003-10-02
GR3036625T3 (en) 2001-12-31
PT726778E (pt) 2001-12-28
HK1036214A1 (en) 2001-12-28
DK0726778T3 (da) 2001-09-24
EP0726778B1 (de) 2001-07-25
IL112583A0 (en) 1995-05-26
EP1090645A3 (de) 2002-02-27
EP0726778A1 (de) 1996-08-21
EP1090645B1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
DE69534676D1 (de) Orale Verabreichung von chemisch modifizierten Proteinen
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
DK642587A (da) Insulinpraeparat
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
DK0851762T3 (da) Farmaceutiske kombinationspræparater, som indeholder erythropoietin og jernpræparater
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
NZ220539A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
RU95121623A (ru) Мазь
IT1251496B (it) Derivati imidazotiadiazolici ad attivita' diuretica, procedimenti per la loro preparazione e composizioni che li contengono
FR2722500B1 (fr) Derives d'acide 2-thienylimidazo(1,2-a) benzimidazole-3-acetique, leur preparation et leur application en therapeutique
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition